Construct: ORF TRCN0000468953

Construct Description:

Construct Type:
ORF
Other Identifiers:
ORF000168.1_s317c1
Derived from:
ccsbBroadEn_11605
DNA Barcode:
ATCGAGGGTCCACGTACCTGTACT
Epitope Tag:
V5
Notes:
No stop codon in insert

Originally Annotated References:

Gene:
RABL2A (11159)

Vector Information:

Vector Backbone:
pLX_317
Pol II Cassette 1:
SV40-PuroR
Pol II Cassette 2:
EF1a-TRCN0000468953
Selection Marker:
PuroR
Visible Reporter:
n/a
Epitope Tag:
n/a

Current transcripts matched by this ORF:

Taxon Gene Symbol Description Transcript Nuc. Match %[?] Prot. Match %[?] Match Diffs[?]
1 human 11159 RABL2A RAB, member of RAS oncogene... NM_001354417.2 100% 100%
2 human 11159 RABL2A RAB, member of RAS oncogene... NM_001306158.2 97.5% 97.3% 671_687delinsAA
3 human 11159 RABL2A RAB, member of RAS oncogene... NM_001306159.2 97.5% 97.3% 671_687delinsAA
4 human 11159 RABL2A RAB, member of RAS oncogene... NM_001354412.2 97.5% 97.3% 671_687delinsAA
5 human 11159 RABL2A RAB, member of RAS oncogene... NM_001354413.2 97.5% 97.3% 671_687delinsAA
6 human 11159 RABL2A RAB, member of RAS oncogene... NM_001354414.2 97.5% 97.3% 671_687delinsAA
7 human 11159 RABL2A RAB, member of RAS oncogene... XM_017003213.1 97.5% 97.3% 671_687delinsAA
8 human 11159 RABL2A RAB, member of RAS oncogene... XM_017003214.1 97.5% 97.3% 671_687delinsAA
9 human 11159 RABL2A RAB, member of RAS oncogene... XM_017003215.1 97.5% 97.3% 671_687delinsAA
10 human 11159 RABL2A RAB, member of RAS oncogene... XM_017003216.1 97.5% 97.3% 671_687delinsAA
11 human 11159 RABL2A RAB, member of RAS oncogene... XM_024452575.1 97.5% 97.3% 671_687delinsAA
12 human 11159 RABL2A RAB, member of RAS oncogene... NM_001354416.2 97% 96.9% 408_409insGCA;668_684delinsAA
13 human 11159 RABL2A RAB, member of RAS oncogene... NM_007082.5 97% 96.9% 408_409insGCA;668_684delinsAA
14 human 11159 RABL2A RAB, member of RAS oncogene... NM_013412.4 97% 96.9% 408_409insGCA;668_684delinsAA
15 human 11159 RABL2A RAB, member of RAS oncogene... XM_017003220.1 97% 96.9% 408_409insGCA;668_684delinsAA
16 human 11159 RABL2A RAB, member of RAS oncogene... XM_017003222.1 97% 96.9% 408_409insGCA;668_684delinsAA
17 human 11158 RABL2B RAB, member of RAS oncogene... NM_001003789.3 96.9% 96.5% (many diffs)
18 human 11158 RABL2B RAB, member of RAS oncogene... NM_001130919.3 96.9% 96.5% (many diffs)
19 human 11158 RABL2B RAB, member of RAS oncogene... NM_001130920.3 96.9% 96.5% (many diffs)
20 human 11158 RABL2B RAB, member of RAS oncogene... NM_001130921.3 96.9% 96.5% (many diffs)
21 human 11158 RABL2B RAB, member of RAS oncogene... NM_001350003.2 96.9% 96.5% (many diffs)
22 human 11158 RABL2B RAB, member of RAS oncogene... NM_001350004.2 96.9% 96.5% (many diffs)
23 human 11158 RABL2B RAB, member of RAS oncogene... XM_017028552.1 96.9% 96.5% (many diffs)
24 human 11158 RABL2B RAB, member of RAS oncogene... XM_017028555.1 96.9% 96.5% (many diffs)
25 human 11158 RABL2B RAB, member of RAS oncogene... XM_024452147.1 96.9% 96.5% (many diffs)
26 human 11158 RABL2B RAB, member of RAS oncogene... NM_001130922.3 96.5% 96% (many diffs)
27 human 11158 RABL2B RAB, member of RAS oncogene... NM_001350005.2 96.5% 96% (many diffs)
28 human 11158 RABL2B RAB, member of RAS oncogene... NM_001350006.2 96.5% 96% (many diffs)
29 human 11158 RABL2B RAB, member of RAS oncogene... NM_001350007.2 96.5% 96% (many diffs)
30 human 11158 RABL2B RAB, member of RAS oncogene... NM_007081.4 96.5% 96% (many diffs)
31 human 11158 RABL2B RAB, member of RAS oncogene... XM_017028556.1 96.5% 96% (many diffs)
32 human 11159 RABL2A RAB, member of RAS oncogene... XM_017003210.1 95% 94.8% 506_523del;689_705delinsAA
33 human 11159 RABL2A RAB, member of RAS oncogene... XM_017003211.1 95% 94.8% 506_523del;689_705delinsAA
34 human 11159 RABL2A RAB, member of RAS oncogene... XM_017003212.1 94.6% 94.4% 408_409insGCA;503_520del;686_702delinsAA
35 human 11158 RABL2B RAB, member of RAS oncogene... NM_001350016.2 94.4% 94% (many diffs)
36 human 11158 RABL2B RAB, member of RAS oncogene... NM_001350017.2 94.4% 94% (many diffs)
37 human 11158 RABL2B RAB, member of RAS oncogene... XM_017028551.1 94% 93.6% (many diffs)
38 human 11159 RABL2A RAB, member of RAS oncogene... NM_001354405.2 93.4% 93.3% 505_534del;701_717delinsAA
39 human 11159 RABL2A RAB, member of RAS oncogene... NM_001354406.2 93.4% 93.3% 505_534del;701_717delinsAA
40 human 11159 RABL2A RAB, member of RAS oncogene... NM_001354407.2 93.4% 93.3% 505_534del;701_717delinsAA
41 human 11159 RABL2A RAB, member of RAS oncogene... NM_001354408.2 93.4% 93.3% 505_534del;701_717delinsAA
42 human 11159 RABL2A RAB, member of RAS oncogene... NM_001354409.2 93.4% 93.3% 505_534del;701_717delinsAA
43 human 11159 RABL2A RAB, member of RAS oncogene... XM_006712208.3 93.4% 93.3% 505_534del;701_717delinsAA
44 human 11159 RABL2A RAB, member of RAS oncogene... XM_006712209.3 93.4% 93.3% 505_534del;701_717delinsAA
45 human 11159 RABL2A RAB, member of RAS oncogene... XM_011510509.2 93.4% 93.3% 505_534del;701_717delinsAA
46 human 11159 RABL2A RAB, member of RAS oncogene... XM_017003203.1 93.4% 93.3% 505_534del;701_717delinsAA
47 human 11159 RABL2A RAB, member of RAS oncogene... XM_017003204.1 93.4% 93.3% 505_534del;701_717delinsAA
48 human 11159 RABL2A RAB, member of RAS oncogene... XM_017003205.1 93.4% 93.3% 505_534del;701_717delinsAA
49 human 11159 RABL2A RAB, member of RAS oncogene... XM_017003207.1 93.4% 93.3% 505_534del;701_717delinsAA
50 human 11159 RABL2A RAB, member of RAS oncogene... NM_001306160.3 93% 92.8% 408_409insGCA;502_531del;698_714delinsAA
51 human 11159 RABL2A RAB, member of RAS oncogene... NM_001354410.2 93% 92.8% 408_409insGCA;502_531del;698_714delinsAA
52 human 11159 RABL2A RAB, member of RAS oncogene... XM_024452573.1 93% 92.8% 408_409insGCA;502_531del;698_714delinsAA
53 human 11158 RABL2B RAB, member of RAS oncogene... NM_001350008.2 92.8% 92.4% (many diffs)
54 human 11158 RABL2B RAB, member of RAS oncogene... NM_001350009.2 92.8% 92.4% (many diffs)
55 human 11158 RABL2B RAB, member of RAS oncogene... NM_001350010.2 92.8% 92.4% (many diffs)
56 human 11158 RABL2B RAB, member of RAS oncogene... NM_001350011.2 92.8% 92.4% (many diffs)
57 human 11158 RABL2B RAB, member of RAS oncogene... NM_001350012.2 92.8% 92.4% (many diffs)
58 human 11158 RABL2B RAB, member of RAS oncogene... XM_017028543.1 92.8% 92.4% (many diffs)
59 human 11158 RABL2B RAB, member of RAS oncogene... XM_017028544.1 92.8% 92.4% (many diffs)
60 human 11158 RABL2B RAB, member of RAS oncogene... XM_017028546.1 92.8% 92.4% (many diffs)
61 human 11158 RABL2B RAB, member of RAS oncogene... NM_001130923.3 92.4% 92% (many diffs)
62 human 11158 RABL2B RAB, member of RAS oncogene... NM_001350013.2 92.4% 92% (many diffs)
63 human 11158 RABL2B RAB, member of RAS oncogene... NM_001350014.2 92.4% 92% (many diffs)
64 human 11158 RABL2B RAB, member of RAS oncogene... NM_001350015.2 92.4% 92% (many diffs)
65 human 11158 RABL2B RAB, member of RAS oncogene... XM_017028547.1 92.4% 92% (many diffs)
66 human 11159 RABL2A RAB, member of RAS oncogene... NM_001306161.2 69.5% 69.4% 216_217ins192;479_495delinsAA
67 human 11159 RABL2A RAB, member of RAS oncogene... NM_001354421.2 69.5% 69.4% 216_217ins192;479_495delinsAA
68 human 11159 RABL2A RAB, member of RAS oncogene... NM_001354423.2 69.5% 69.4% 216_217ins192;479_495delinsAA
69 human 11159 RABL2A RAB, member of RAS oncogene... XM_017003226.1 69.5% 69.4% 216_217ins192;479_495delinsAA
70 human 11159 RABL2A RAB, member of RAS oncogene... NM_001354424.2 69.1% 68.9% 216_217ins195;476_492delinsAA
71 human 11159 RABL2A RAB, member of RAS oncogene... NM_001354418.2 66.6% 66.5% 216_217ins192;313_342del;509_525delinsAA
72 human 11159 RABL2A RAB, member of RAS oncogene... NM_001354419.2 66.6% 66.5% 216_217ins192;313_342del;509_525delinsAA
73 human 11159 RABL2A RAB, member of RAS oncogene... XM_017003223.1 66.6% 66.5% 216_217ins192;313_342del;509_525delinsAA
74 human 11159 RABL2A RAB, member of RAS oncogene... NM_001354426.2 60.4% 60.2% 0_1ins255;416_432delinsAA
75 human 11159 RABL2A RAB, member of RAS oncogene... NM_001354425.2 57.8% 57.7% 0_1ins255;250_279del;446_462delinsAA
76 human 11159 RABL2A RAB, member of RAS oncogene... XM_017003230.1 57.8% 57.7% 0_1ins255;250_279del;446_462delinsAA
77 human 11159 RABL2A RAB, member of RAS oncogene... NM_001354427.2 57.3% 54.5% 0_1ins196;20_21ins80;395_411delinsAA
78 human 11159 RABL2A RAB, member of RAS oncogene... NM_001354428.2 56.9% 54.1% (many diffs)
79 human 11159 RABL2A RAB, member of RAS oncogene... XM_024452576.1 54.9% 52.3% (many diffs)
80 human 11158 RABL2B RAB, member of RAS oncogene... XM_017028559.2 48.4% 42.1% (many diffs)
81 human 11159 RABL2A RAB, member of RAS oncogene... XR_002959036.1 26.8% 1_200del;609_955del;1218_2500delinsAA
82 human 11159 RABL2A RAB, member of RAS oncogene... NR_148882.2 26% 1_188del;482_483ins112;747_2029delinsAA
83 human 11159 RABL2A RAB, member of RAS oncogene... NR_148881.2 26% 1_192del;486_487ins112;751_2033delinsAA
84 human 11159 RABL2A RAB, member of RAS oncogene... NR_148879.2 25.9% 1_188del;484_485ins115;744_2026delinsAA
85 human 11159 RABL2A RAB, member of RAS oncogene... NR_148880.2 22% (many diffs)
86 mouse 68708 Rabl2 RAB, member RAS oncogene fa... NM_026817.3 84.5% 82.5% (many diffs)
87 mouse 68708 Rabl2 RAB, member RAS oncogene fa... XM_006521326.3 84.1% 82.1% (many diffs)
88 mouse 68708 Rabl2 RAB, member RAS oncogene fa... XM_006521327.3 71.6% 70.9% (many diffs)
89 mouse 68708 Rabl2 RAB, member RAS oncogene fa... XM_006521329.3 52.5% 49.5% (many diffs)
90 mouse 68708 Rabl2 RAB, member RAS oncogene fa... XM_011245717.2 52.5% 49.5% (many diffs)
Download CSV

Sequence Information

Note: uppercase bases indicate empirically verified sequence.

ORF start:
69
ORF end:
741
ORF length:
672
Sequence:
1tcttccattt caggtgtcgt gaggctagca tcgattgatc aacaagtttg tacaaaaaag
61ttggcaccat ggcagaagac aaaaccaaac cgagtgagtt ggaccaaggg aagtatgatg
121ctgatgacaa cgtgaagatc atctgcctgg gagacagcgc agtgggcaaa tccaaactca
181tggagagatt tctcatggat ggctttcagc cacagcagct gtccacgtac gccctgaccc
241tgtacaagca cacagccacg gtagatggca agaccatcct tgtggacttt tgggacacgg
301caggccagga gcggttccag agcatgcatg cctcctacta ccacaaggcc catgcctGCA
361TCATGGTGTT TGATATACAG AGGAAAGTCA CCTATAGGAA CCTGAGCACC TGGTATACAG
421AGCTTCGGGA GTTCAGGCCA GAGATCCCAT GCATCGTGGT GGCCAATAAA ATTGATGCAG
481ACATAAACGT GACCCAAAAA AGCTTCAATT TTGCCAAGAA GTTCTCCCTG CCCCTGTATT
541TCGTCTCGGC TGCTGATGGT ACCAATGTTG TGAAGCTCTT CAATGATGCA ATTCGATTAG
601CTGTGTCTTA CAAACAGAAC TCCCAGGACT TCATGGATGA GATTTTTCAG GAGCTCGAGA
661ACTTCAGCTT GGAGCAGGAA GAGGAGGACG TGCCAGACCA GGAACAGAGC AGCAGCATCG
721AGACCCCATC AGAGGAGGAA TTGCCAACTT TCTTGTACAA AGTGGTTGAT ATCGGTAAGC
781CTATCCCTAA CCCTCTCCTC GGTCTCGATT CTACGTAGTA ATGAACTAGT CCGTAACTTG
841AAAGTATTTC GATTTCTTGG CTTTATATAT CTTGTGGAAA GGACGAATCG AGGGTCCACG
901TACCTGTACT ACGCGTTAAG TCgacaatca acctctggat tacaaaattt gtgaaagatt

Download FASTA (ORF) (Full)

GPP Web Portal Terms of Service

Effective Date: December 8, 2025
By using this site, you agree to our terms and conditions below.

Overview of Terms

The data made available on this website were generated for research purposes and are not intended for clinical or commercial uses. Commercial use (or other use for profit-making purposes) of the GPP Web Portal and its tools, is not permitted under these terms and may require a separate license agreement from Broad or its contributors. For more information, please contact partnering@broadinstitute.org.

The original data may be subject to rights claimed by third parties, including but not limited to, patent, copyright, other intellectual property rights, biodiversity-related access and benefit-sharing rights. It is the responsibility of users of Broad Institute services to ensure that their use of the data does not infringe any of the rights of such third parties.

Any questions or comments concerning these Terms of Use can be addressed to: legal@broadinstitute.org.

By accessing and viewing this GPP Web Portal, you agree to the following terms and conditions:

Attribution

You agree to acknowledge the Broad Institute (e.g., in publications, services or products) for any of your use of its online services, databases or software in accordance with good scientific practice. You agree to use the acknowledgment wording provided for the relevant tools as indicated on the FAQ for each tool.

Updating the Terms of Use

We reserve the right to update these Terms of Use at any time. When alterations are inevitable, we will attempt to give reasonable notice of any changes by placing a notice on our website, but you may wish to check each time you use the website. The date of the most recent revision will appear on this, the "GPP Web Portal Terms of Use" page. If you do not agree to these changes, please do not continue to use our online services. We will also make available an archived copy of the previous Terms of Use for comparison.

Indemnification and Disclaimer of Warranties

You are using this GPP Web Portal at your own risk, and you hereby agree to hold Broad and its contributors and their trustees, directors, officers, employees, and affiliated investigators harmless for any third party claims which may arise from your use of the GPP Web Portal, the tools available therein, or any portion thereof. Further, you agree to indemnify Broad, its contributors, and its and their trustees, directors, officers, employees, affiliated investigators, students, and affiliates for any loss, costs, claims, damages, or other liabilities arising from any unpermitted commercial or profit-making use you make of the GPP Web Portal. The GPP Web Portal is a research tool and is provided "as is". Broad does not represent that the GPP Web Portal is free of errors or bugs or suitable for any particular tasks.

ANY EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, OR THE ABSENCE OF LATENT OR OTHER DEFECTS ARE DISCLAIMED. IN NO EVENT SHALL BROAD OR ITS CONTRIBUTORS BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, OR CONSEQUENTIAL DAMAGES HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, WHETHER IN CONTRACT, STRICT LIABILITY, OR TORT (INCLUDING NEGLIGENCE OR OTHERWISE) ARISING IN ANY WAY OUT OF THE USE OF THE GPP WEB PORTAL, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGE.

Governing Law

The terms and conditions herein shall be construed, governed, interpreted, and applied in accordance with the internal laws of the Commonwealth of Massachusetts, U.S.A. Furthermore, by accessing, downloading, or using the Database, You consent to the personal jurisdiction of, and venue in, the state and federal courts within Massachusetts with respect to Your download or use of the Database.